Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

This study compares a new EGFR-targeting drug called firmonertinib to standard platinum-based chemotherapy as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) that has specific uncommon EGFR mutations (called PACC or L861Q mutations). These mutations are less common and may respond differently than the typical EGFR mutations. **You may be eligible if...** - You are 18 or older with locally advanced or metastatic non-squamous NSCLC (stage IIIB, IIIC, or IV) - Your tumor has a confirmed PACC or L861Q EGFR mutation on central laboratory testing - You have not received any prior systemic treatment for advanced-stage disease - You are in good general health (ECOG 0 or 1) with at least one measurable tumor **You may NOT be eligible if...** - Your tumor contains a significant proportion of neuroendocrine cells (more than 10%) - You have had prior EGFR-targeted therapy for advanced disease - You do not have the specific EGFR mutations tested in this study Talk to your doctor to see if this trial is right for you.